Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
Dassault Systèmes (OTC:DASTY) announced that its Medidata brand has extended a 10-plus-year collaboration with Sanofi to support clinical research and speed therapy development. Sanofi will use Medidata Patient, Data, and Study Experiences, including AI-embedded, platform-based solutions and decentralized trial capabilities, with Medidata supplying consulting and end-to-end operational support. The extension aims to unify clinical workflows, reduce silos, and shorten delays to accelerate new therapies and improve patient journeys.
Dassault Systèmes (OTC:DASTY) ha annunciato che il suo marchio Medidata ha esteso una collaborazione pluriennale di oltre dieci anni con Sanofi per supportare la ricerca clinica e accelerare lo sviluppo delle terapie. Sanofi utilizzerà Medidata Patient, Data e Study Experiences, inclusi soluzioni basate sulla piattaforma con IA integrate e capacità di trial decentralizzati, con Medidata che fornirà consulenza e supporto operativo end-to-end. L’estensione mira a unificare i flussi di lavoro clinici, ridurre i silos e accorciare i ritardi per accelerare nuove terapie e migliorare i percorsi dei pazienti.
Dassault Systèmes (OTC: DASTY) anunció que su marca Medidata ha ampliado una colaboración de más de diez años con Sanofi para apoyar la investigación clínica y acelerar el desarrollo de terapias. Sanofi utilizará Medidata Patient, Data y Study Experiences, incluidas soluciones basadas en plataforma con IA integrada y capacidades de ensayos descentralizados, con Medidata proporcionando consultoría y soporte operativo de extremo a extremo. La extensión tiene como objetivo unificar los flujos de trabajo clínicos, reducir los silos y acortar los retrasos para acelerar nuevas terapias y mejorar la experiencia de los pacientes.
Dassault Systèmes (OTC: DASTY)가 Medidata 브랜드가 Sanofi와의 협력을 10년을 넘는 기간으로 확장했다고 발표했습니다. 이는 임상 연구를 지원하고 치료 개발을 가속화하기 위함입니다. Sanofi는 Medidata Patient, Data, and Study Experiences를 포함한 AI가 내장된 플랫폼 기반 솔루션 및 분산 임상 역량을 활용하되, Medidata는 컨설팅 및 엔드투엔드 운영 지원을 제공합니다. 확장의 목적은 임상 워크플로를 통합하고 사일로를 줄이며 지연을 단축하여 새로운 치료제를 신속히 개발하고 환자 여정을 개선하는 데 있습니다.
Dassault Systèmes (OTC:DASTY) a annoncé que sa marque Medidata a étendu une collaboration de plus de dix ans avec Sanofi pour soutenir la recherche clinique et accélérer le développement des thérapies. Sanofi utilisera Medidata Patient, Data et Study Experiences, y compris des solutions basées sur la plateforme avec IA intégrée et des capacités d’essais décentralisés, Medidata fournissant des services de conseil et un support opérationnel de bout en bout. Cette extension vise à unifier les flux de travail cliniques, à réduire les silos et à diminuer les retards afin d’accélérer les nouvelles thérapies et d’améliorer le parcours des patients.
Dassault Systèmes (OTC: DASTY) hat bekannt gegeben, dass seine Marke Medidata die über zehn Jahre laufende Zusammenarbeit mit Sanofi verlängert hat, um die klinische Forschung zu unterstützen und die Therapentwicklungen zu beschleunigen. Sanofi wird Medidata Patient, Data und Study Experiences nutzen, einschließlich KI-integrierter, plattformbasierter Lösungen und dezentraler Studienfähigkeiten, wobei Medidata Beratung und umfassende operative Unterstützung liefert. Die Erweiterung zielt darauf ab, klinische Arbeitsabläufe zu vereinheitlichen, Silos zu reduzieren und Verzögerungen zu verkürzen, um neue Therapien zu beschleunigen und die Patientenerlebnisse zu verbessern.
Dassault Systèmes (OTC: DASTY) أعلنت أن علامتها Medidata قد وسّعت تعاوناً يمتد لأكثر من عشر سنوات مع Sanofi لدعم البحث السريري وتسريع تطوير العلاجات. ستستخدم Sanofi حلول Medidata Patient, Data, وStudy Experiences، بما في ذلك حلول قائمة على المنصة مع ذكاء اصطناعي مدمج وإمكانات التجارب الموزعة، مع أن تقدم Medidata الاستشارات والدعم التشغيلي الشامل من البداية للنهاية. يهدف التمديد إلى توحيد سير العمل السريري، وتقليل العزلة، وتقليل التأخيرات لتسريع تطوير العلاجات الجديدة وتحسين مسار المرضى.
达索系统（OTC: DASTY）宣布，其 Medidata 品牌已与赛诺菲扩展超过十年的合作伙伴关系，以支持临床研究并加速疗法开发。赛诺菲将使用 Medidata Patient、Data 和 Study Experiences，包括嵌入 AI 的平台解决方案和去中心化试验能力，Medidata 将提供咨询和端到端的运营支持。此次扩展旨在统一临床工作流程、减少信息孤岛、缩短延迟，从而加速新疗法的开发并改善患者就诊体验。
- 10-plus-year collaboration extension with Sanofi
- Sanofi to adopt Medidata Patient, Data, and Study Experiences
- Inclusion of AI-embedded platform solutions across clinical workflows
- Medidata to provide consulting and end-to-end operational support
- Sanofi will use Medidata decentralized clinical trial capabilities
- None.
Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care
New York – Oct. 23, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration with Sanofi in clinical research. As part of this extension Sanofi will use the Medidata Patient, Data, and Study Experiences, building on the organizations’ vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.
The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge can help advance studies, amplifying the development of therapies with greater precision and impact.
Sanofi will employ Medidata’s expertise and capabilities in decentralized clinical trials as part of the extension of this agreement. Medidata will provide consulting and end-to-end operational support.
“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through this agreement, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the clinical development process.”
To learn more about the Medidata Experiences, please visit here.
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com.
Contact:
Medidata PR
Medidata.PR@3ds.com
Analyst Relations
Attachment
FAQ
What did Dassault Systèmes announce about Medidata and Sanofi on October 28, 2025?
How will the Medidata collaboration affect Sanofi's clinical trials (DASTY)?
What specific Medidata solutions will Sanofi use under the DASTY collaboration extension?
Does the announcement include financial terms or revenue guidance for DASTY?
What operational support will Medidata provide Sanofi under the extended agreement (DASTY)?
